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• FAM19A4/mir124-2 triage of HPV-positive self-samples is a feasible and promising tool
• FAM19A4/mir124-2 analysis identiﬁes HPV-positive women at risk of cervical cancer.
• FAM19A4/mir124-2 analysis performs equally well in lavage and brush self-samples.
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Available online 3 March 2016Objectives. DNA methylation analysis of cancer-related genes is a promising tool for HPV-positive women to
identify those with cervical (pre)cancer (CIN3+) in need of treatment. However, clinical performance of meth-
ylationmarkers can be inﬂuenced by the sample type utilized.Wedescribe amultiplex quantitativemethylation-
speciﬁc PCR that targets FAM19A4 andmir124-2 loci, to detect CIN3+ using both HPV-positive lavage- and brush
self-samples.
Methods.We determined methylation thresholds for clinical classiﬁcation using HPV-positive training sets
comprising lavage self-samples of 182 women (including 40 with CIN3+) and brush self-samples of 224
women (including 61 with CIN3+). Subsequently, independent HPV-positive validation sets of 389 lavage
self-samples (including 78 with CIN3+), and 254 brush self-samples (including 72 with CIN3+) were tested
using the preset thresholds. Furthermore, the clinical performance of combined methylation analysis and
HPV16/18 genotyping was determined.
Results. Training set analysis revealed similar FAM19A4 and mir124-2 thresholds for both self-sample types
to yield highest CIN3+ sensitivity at 70% speciﬁcity. Validation set analysis resulted in a CIN3+ sensitivity of
70.5% (95%CI: 60.4–80.6) at a speciﬁcity of 67.8% (95%CI: 62.7–73.0) for lavage self-samples, and a CIN3+
sensitivity of 69.4% (95%CI: 58.8–80.1) at a 76.4% (95%CI: 70.2–82.6) speciﬁcity for brush self-samples. In combi-
nation with HPV16/18 genotyping, CIN3+ sensitivity and speciﬁcity were 88.5% (95%CI: 81.4–95.6) and 46.0%
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342 L.M.A. De Strooper et al. / Gynecologic Oncology 141 (2016) 341–347Conclusions. FAM19A4/mir124-2 methylation analysis performs equally well in HPV-positive lavage- and
brush self-samples to identify women with CIN3+. In combination with HPV16/18 genotyping, signiﬁcantly
higher CIN3+ sensitivities are obtained, at decreased speciﬁcity.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Background
A substantial subset of women does not participate in population-
based cervical screening, which compromises the effectiveness of the
screening program [1]. These non-responders are at increased risk of de-
veloping cervical cancer, indicating the need for recruitment of these
women into screening [1,2]. Offering devices for self-collection of
(cervico-)vaginal specimens has prospects to increase screening compli-
ance [3–6]. Self-collected (cervico-)vaginal specimens can be tested for
the presence of DNA from high-risk types of human papillomavirus
(HPV) in a laboratory (i.e., HPV self-sampling). When using validated
PCR assays, HPV testing on self-samples can have similar accuracy for de-
tecting cervical (pre)cancer (CIN3+) as HPV testing of physician-taken
samples [4,7–12]. Therefore, it is expected that HPV self-sampling with
validated combinations of self-collection devices andHPV tests,will be in-
creasingly adopted in future HPV-based screening programs [10,13,14].
However, HPV testing cannot distinguish transient from persistent,
clinically relevant high-risk HPV infections. Therefore, additional testing
(i.e., triage) is essential to identify HPV-positive women with CIN le-
sions in need of treatment. This approach will reduce over-referral,
unnecessary colposcopies, and overtreatment of women without clini-
cally meaningful HPV infections. Currently, various triage strategies for
hrHPV-positivewomen have been considered including repeat cytology
testing [15], HPV16/18 genotyping [16,17] (and combinations thereof
[15,18]), HPV E7 mRNA analysis [19,20], viral and/or host cell DNA
methylation analysis [21–23], p16/ki67 cytological dual staining [24,
25] and analysis of host cell gene ampliﬁcation such as TERC [26,27].
Of these, cytology, either or not combined with HPV16/18 genotyping
analysis, is currently most widely accepted [15,28]. However, cytology
on self-collected (cervico-)vaginal specimens is unreliable [29]. There-
fore, cytology triage would require an additional visit to a clinician for
cervical scrape collection. The resulting prerequisite for cervical cytolo-
gy for previous non-responder women, has been associated with loss to
follow-up and has shown to extend the diagnostic track [22]. This
process could be simpliﬁed substantially by triage testing directly on
HPV-positive self-samples by non-morphological, molecular methods.
Although HPV16/18 genotyping asmolecular test is directly applica-
ble to self-samples and detects women with increased cervical cancer
risk, a non-negligible fraction of (pre)cancers associated with non-
HPV16/18 high-risk HPV types will be missed when using genotyping
alone [30]. As an alternative or additive tool, methylation markers that
reﬂect molecular events in host cells contributing to cervical carcino-
genesis are highly promising [31–33]. Previous studies have revealed
that promoter methylation of host cell genes such as FAM19A4 and
mir124-2, increases with cervical disease severity [34–36]. Methylation
levels of FAM19A4 and mir124-2 are particularly high in women with
cervical cancer and advanced high-grade lesions, the latter character-
ized by a longer duration (≥5 years) of a preceding high-risk HPV infec-
tion [31,35,37,38]. Of interest, methylation analysis on HPV-positive
self-collected lavage samples as direct molecular triage tool usingMAL
and mir124-2 loci has reported to be clinically non-inferior to cytology
triage on a subsequent physician-taken scrape in a recent randomized
controlled trial [22]. In addition, methylation analysis on these samples
could be combined with HPV16/18 genotyping to reach higher CIN3+
sensitivity [30].
With an increasing interest in self-collection for HPV-based cervical
screening programs [39,40], it is of importance to gain more clinical
performance data on methylation marker analysis of HPV-positiveself-samples. Since performance of methylation markers can be inﬂu-
enced by the type of sample utilized [41], performance evaluation in dif-
ferent self-sample types is necessary to determine its broader utility.
Unlike samples collected by lavage-based device [22,33], evaluation of
brush-collected self-samples by methylation analysis is restricted to
feasibility studies so far [32]. Furthermore, no studies with large sample
numbers have compared the performance of DNAmethylationmarkers
on HPV-positive lavage and brush self-samples.
Here, we conducted a post-hoc analysis on 1049 HPV-positive self-
samples from previous PROHTECT studies that had been collected by
either lavage- and or brush-based self-collection devices [5,22,42]. We
evaluated a multiplex quantitative methylation-speciﬁc PCR (qMSP)
that targets FAM19A4 and mir124-2 loci. The performance of the qMSP
assay in terms of analytical sensitivity, analytical speciﬁcity, and daily-
use reproducibility is described. In addition, the clinical performance of
the assay, either or not combined with HPV16/18 genotyping, for detec-




For the training set, 375 HPV-positive (GP5+/6 + PCR) cervico-
vaginal lavage self-samples collected with the second generation
Delphi-screener (Delphi-Bioscience, the Netherlands) from non-
responder women participating in the PROHTECT-3B trial were avail-
able. The ﬂowchart of this training set is shown in Fig. 1A (left panel).
These samples are further referred to as lavage self-samples. The trial
was registered in the trial register as NTR3350. Detailed characteristics,
inclusion criteria and follow-up procedures of the PROHTECT-3B trial
have been described previously [42]. Of the HPV-positive women, 15
women had no cytological or histological follow-up and were excluded
from analysis. Of the remaining 360 women, 251 women reached a
study-endpoint [i.e., either a histological outcome, classiﬁed as cer-
vical cancer, cervical intraepithelial neoplasia (CIN) grade 3 (CIN3),
CIN2, CIN1, or absence of CIN (CIN0) or a combined normal cytology
and HPV negative outcome]. Since CIN2 lesions often represent a
misclassiﬁed CIN1 or CIN3, women with CIN2 lesions (n = 36) were
excluded from the training set. From the remaining 215 women, 182
had sufﬁcient quantities of the self-sample with qualitatively adequate
DNA left for qMSP analysis. Of them, 40 were histologically diagnosed
with CIN3+ [i.e., 33 CIN3, 6 squamous cell carcinoma (SCC), and 1 ade-
nocarcinoma (AdCA)] with amedian age of 38 years (range 33–58). The
remaining 142 women had no evidence of CIN2+ (also referred to as
womenwith ≤CIN1). Of these, 42 had histologically-conﬁrmed absence
of CIN, 36 had CIN1 and 64 women had both a negative HPV test and
normal cytology at follow-up The median age of women with ≤CIN1
was 38 years (range 33–64).
For the validation set, 515 HPV-positive (GP5+/6 +−PCR) lavage
self-samples, collected with the ﬁrst generation Delphi-screener
(Delphi-Bioscience, the Netherlands) were available from non-
responder women participating in the methylation triage arm of the
PROHTECT-3A trial (NTR2606). The ﬁrst and second generation
Delphi-screener perform equal in DNA yield and HPV-detection [43].
The ﬂowchart of the validation set is shown in Fig. 1A (right panel). De-
tailed characteristics, inclusion criteria and follow-up procedures of the
PROHTECT-3A trial have been described previously [22]. Of the 515
Fig. 1. Overview of the study populations. The training and validation sets for lavage self-samples (1A), and the training and validation sets for brush self-samples (1B) are presented.
HPV= human papillomavirus, CIN = cervical intraepithelial neoplasia.
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tailed above) within 18 months of follow-up. Of the 408 women, 389
had sufﬁcient quantities left of the self-sample with qualitatively
adequate DNA for qMSP analysis. This series included 78 women
who were histologically diagnosed with CIN3+ [i.e., 70 CIN3, 5 SCC, 2
adenocarcinoma in situ (ACIS) and 1 AdCA] with a median age of
38 years (range 33–58) and 41 women with CIN2 with a median age
of 43 years (range 33–58). The remaining 270 women had no evidence
of CIN2+. Of these, 125 had histologically-conﬁrmed absence of CIN
and 76 had CIN1. The remaining 69 women had both a negative HPV
test and normal cytology at follow-up. The median age of this group
was 43 years (range 33–63).
2.1.2. Brush-collected self-samples
For the training set, 409 HPV-positive (GP5+/6 + PCR) vaginal
brush self-samples collected with the Evalyn brush (Rovers Medical
Devices, the Netherlands) from non-responder women participating
in the PROHTECT-3B trial [42] were available. The ﬂowchart of this
training set is shown in Fig. 1B (left panel). After self-sampling, the
brushes were sent dry to the laboratory where they were placed into
1.5 ml PreservCyt medium (Hologic, USA) before further processing.
Of the HPV-positive women, 18 women had no cytological or histolog-
ical follow-up and were excluded from analysis. From the 391 HPV-
positive women, those who reached a study-endpoint (as detailed
above), except for those with CIN2 (n = 25, as explained above), and
of whom sufﬁcient quantities were left of the self-sample with qualita-
tively adequate DNA for qMSP analysis, were included in the training
set. The remaining series of 224 women included 61 women who
were histologically diagnosed with a CIN3+ lesion (i.e., 53 CIN3, 5
SCC, and 3 AdCA) with a median age of 38 years (range 33–59) The
other 163 women had no evidence of CIN2+. Of these, 57 hadhistologically-conﬁrmed absence of CIN, 34 had CIN1, and 72 women
had both a negative HPV test and normal cytology at follow-up Theme-
dian age of women with ≤CIN1 was 38 years (range 33–63).
For the validation set, 541 HPV-positive (GP5+/6 + PCR) vaginal
brush self-samples from non-responder women participating in the
PROHTECT-2 trial (NTR1851), were available. These samples were col-
lected with the VibaBrush (Rovers Medical Devices, the Netherlands).
The ﬂowchart of the validation set is shown in Fig. 1B (right panel).
After self-sampling, the brushes were placed in 1.5 ml universal collec-
tion medium (Qiagen, USA) before sending to the laboratory. Detailed
characteristics, inclusion criteria and follow-up procedures of the
PROHTECT-2 trial have been described previously [7]. From the 541
HPV-positive women, only those who reached a study-endpoint (as
detailed above) within 36 months of follow-up, and of whom sufﬁcient
quantities were left of the self-sample with qualitatively adequate DNA
for qMSP analysis, were included in the validation set (n = 254).
Of these, 72 women were histologically diagnosed with a CIN3+
lesion [i.e., 67 CIN3, 3 SCC, 1 ACIS and 1 AdCA] and had a median age
of 36 years (range 31–61). 27 women were diagnosed with CIN2
and had a median age of 36 years (range 31–56). The remaining 155
women had no evidence of CIN2+. Of these women, 24 had
histologically-conﬁrmed absence of CIN, 24 had CIN1, and 107 women
had both a negative HPV test and normal cytology at follow-up. Theme-
dian age of this group was 36 years (range 30–62).
All PROHTECT trials had ethical approval by the National Health
Council and all participants gave informed consent.
2.2. Cytology and histology
Women with an HPV-positive self-sample were referred for a
colposcopy-directed biopsy in case of a positive triage test at baseline.
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repeat co-test (HPV and cytology) after 6–12 months. If at least one of
these tests was abnormal (i.e. abnormal cytology (≥borderline or mild
dyskaryosis) or hrHPV-positive), women were referred for colposcopy-
directed biopsy as well. Biopsies taken at colposcopy were histologically
assessed in participating hospitals and classiﬁed as normal (CIN0),
CIN1, CIN2, CIN3 or invasive cancer, according to international criteria
[44]. Women were treated according to standard procedures in the
Netherlands. Cervical scrapes were classiﬁed according to the CISOE-A
classiﬁcation (reporting on Composition, Inﬂammation, Squamous,
Other and endometrium, Endocervical cylindrical epithelium, and Ade-
quacy) used in the Netherlands [45]. The results can be translated into
the Bethesda classiﬁcation [46] in which borderline or mild dyskaryosis
(BMD) equals ASC-US/ASC-H/LSIL, and NBMD equals high-grade squa-
mous intraepithelial lesion (HSIL).
2.2.1. DNA isolation and HPV genotyping
DNA from lavage and brush self-samples was isolated using the
Nucleo-Mag 96 Tissue kit (Macherey-Nagel, Germany) and Microlab
Star robotic system (Hamilton, Germany) according to manufacturers'
protocol [47]. In the PROHTECT-3 trials, all samples were tested for
high-risk HPV (hrHPV) DNA by the clinically validated hrHPV GP5+/
6 + PCR (EIA HPV GP HR kit, Diassay, The Netherlands) according
to the manufacturer's protocol [48]. In PROHTECT-3A, subsequent
hrHPV genotyping was performed using Luminex suspension array
technology [49]. In the PROHTECT-2 trial, samples were tested for
hrHPV using the Hybrid Capture-2® (HC2, Qiagen, USA) according to
manufacturer's protocol [50]. All HC2 positive samples were subse-
quently tested by GP5+/6 + PCR and subjected to hrHPV genotyping
by the reverse line blot assay [51]. In the current study, only samples
that were GP5+/6 + PCR-positive were used.
2.2.2. Bisulphite treatment and qMSP methylation analysis
Isolated DNA was subjected to bisulphite treatment using the
EZ DNAMethylation Kit (Zymo Research, USA) as described previously
[52,53]. Bisulphite-converted DNA (50 ng) was used as template
for DNAmethylation analysis. DNAmethylation analysiswas performed
by amultiplex qMSP assay targeting FAM19A4 andmir124-2 loci, aswell
as ACTB as a sample quality control. Analyses were performed on an ABI
7500 real-time PCR-system (Applied Biosystems, USA). For each target,
Quantiﬁcation Cycle (Cq) values were measured at a ﬁxed ﬂuorescence
threshold. The result of a sample is expressed in ΔΔCq ratio being a
measure for hypermethylation using the 2-ΔΔCq method [54]. A plasmid
containing all amplimer sequences (i.e., ACTB, FAM19A4, andmir124-2)
was used as ampliﬁcation target to assess the analytical sensitivity.
Serial 10-fold plasmid dilutions (range from 750,000 to 1 copy per reac-
tion) were analysed in duplicate in two independent qMSP runs. The
analytical sensitivity was determined as the lowest dilution giving
4 out of 4 positive results (Cq b 40). To assess the analytical speciﬁcity,
bisulphite-converted unmethylated DNA from primary keratinocytes
and unmodiﬁed DNA (i.e., pool of non-bisulphite treated DNA from cer-
vical samples) were analysed in quadruplicate. The reproducibility of
the assay based on ΔΔCq values was evaluated by duplicate measure-
ment in independent qMSP runs of bisulphite-converted DNA of 30
HPV-positive cervical samples.
2.2.3. Data and statistical analysis
First, both training sets (lavage self-samples and brush self-samples,
separately) were used to deﬁne clinical decision points, i.e., thresholds
for positivity of the triage assay. At a predeﬁned speciﬁcity value of
70% for CIN3+, an optimization procedure was performed to calculate
themaximumcorrespondingCIN3+sensitivity over all possible thresh-
old values for the combined marker panel. The deﬁned methylation
thresholds converted the test result into a categorical variable leading
to an optimal CIN3+ sensitivity at 70% CIN3+ speciﬁcity level.
The thresholds were subsequently evaluated in the two independentvalidation sets (lavage and brush, respectively). The primary outcome
was CIN3+ detection and the secondary outcome was CIN2+ detec-
tion. In the validation sets, all samples were additionally evaluated for
the clinical performance of FAM19A4/mir124-2 methylation analysis
combined with HPV16/18 genotyping. Sensitivity, speciﬁcity, positive
predictive value (PPV), and negative predictive value (NPV)were deter-
mined for outcome CIN3+ and CIN2+with 95%Wald conﬁdence inter-
vals. The colposcopy referral rate was calculated as the proportion of
HPV-positive women who had a positive triage test result. Analyses
were performed in the R package (version 2.15). Additional calculations
were performed in IBM SPSS Statistics 20 and Excel.
3. Results
3.1. Analytical performance
For assessing DNA methylation of FAM19A4 and mir124-2, a multi-
plex qMSP assay was used. The analytical sensitivity of the assay was
2.5 copies of methylated target per PCR reaction for both FAM19A4
andmir124-2, and the reference gene ACTB. The assay revealed no pos-
itive signals with bisulphite-converted unmethylated DNA nor non-
bisulphite treated DNA of cervical samples, showing a high analytical
speciﬁcity. The assay demonstrated a high reproducibility on HPV-
positive cervical samples with Pearson correlation coefﬁcients between
the ΔΔCq values of 0.988 for FAM19A4 (Fig. 2A) and 0.970 formir124-2
(Fig. 2B).
3.2. Clinical performance
Using the training sets of HPV-positive lavage and brush self-
samples separately, methylation thresholds for FAM19A4 and mir124-2
were determined that resulted in a maximum CIN3+ sensitivity at a
preset speciﬁcity of 70%. Of interest, these thresholds did not differ
between the different sample types (i.e., HPV-positive lavage compared
to brush self-samples). According to the thresholds, samples withΔΔCq
ratios above the respective threshold for at least one of the targets
(FAM19A4 and/or mir124-2) were rated as test-positive, while samples
with ΔΔCq ratio of both targets below their threshold were rated
as test-negative. The use of these thresholds resulted in CIN3+ sensitiv-
ities of 75.0% (95%CI: 61.6–88.4) and 72.1% (95%CI: 60.9–83.4) in the
training sets of HPV-positive lavage self-samples and brush self-
samples, respectively.
Next, the clinical performance of the multiplex qMSP assay was
validated on independent sets of HPV-positive lavage and brush self-
samples. Sensitivities, speciﬁcities, PPV, NPV and referral rate for colpos-
copy for endpoints CIN3+ and CIN2+ are presented in Table 1 and
Supplementary Table 1, respectively. At the predeﬁned threshold of
70%, a CIN3+ sensitivity of 70.5% (95%CI: 60.4–80.6) at a speciﬁcity of
67.8% (95%CI: 62.7–73.0) was obtained for HPV-positive lavage self-
samples. For CIN2+, a sensitivity of 63.9% (95%CI: 55.2–72.5) at 70.7%
(95%CI: 65.3–76.2) speciﬁcity was obtained. In the validation set of
HPV-positive brush self-samples, a CIN3+ sensitivity of 69.4% (95%CI:
58.8–80.1) at a speciﬁcity of 76.4% (95%CI: 70.2–82.5), and a CIN2+
sensitivity of 59.6% (95%CI: 49.9–69.3) at 78.1 (95%CI: 71.5–84.5) spec-
iﬁcity was obtained. Of note, all women with cervical carcinomas
(lavage, n = 13; brush, n = 12) were scored methylation positive on
their self-sample by the FAM19A4/mir124-2methylation marker assay
at the predeﬁned 70% speciﬁcity threshold.
After combining FAM19A4/mir124-2 methylation analysis with
HPV16/18 genotyping, CIN3+ sensitivities increased and speciﬁcities
decreased for both self-sample types. In lavage self-samples, a CIN3+
sensitivity of 88.5% (95%CI: 81.4–95.6) at a speciﬁcity of 46.0% (95%CI:
40.4–51.5) was observed. In brush self-samples, a CIN3+ sensitivity of
84.7% (95%CI: 76.4–93.0) at a speciﬁcity of 54.9% (95%CI: 47.7–62.2)
was observed (Table 1). For CIN2+, a similar tendency is seen (Supple-
mentary Table 1).
Fig. 2. Reproducibility of the ΔΔcq ratios of FAM19A4 (A) andmir124-2 (B) between two independent qMSP runs.
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In this study, we evaluated FAM19A4/mir124-2methylation analysis
for lavage- and brush-based self-samples to detect cervical (pre)cancer
in HPV-positive women. In comparison to theMAL/mir124-2 triage test
that was prospectively evaluated in HPV-positive lavage self-samples
in a screening setting [22], the current assay shows a similar CIN3+sen-
sitivity at a higher speciﬁcity. Since the FAM19A4/mir124-2 assay fea-
tures likewise clinical performance in HPV-positive brush-collected
self-samples as well as lavage-collected self-samples, it can be consid-
ered as a promising, universal triage test for HPV-positive (cervico-
)vaginal self-samples collected by different self-collection devices. In
combination with HPV16/18 genotyping, signiﬁcantly higher sensitivi-
ties were obtained, yet at the cost of decreased speciﬁcities. Our study
ﬁndings support further validation of cervical screening studies with
HPV testing combined with triage by FAM19A4/mir124-2methylation
analysis on self-collected (cervico-)vaginal specimens. To our knowl-
edge this study is the ﬁrst to evaluate in large sample series whether
DNA methylation analysis is equally applicable to both HPV-positive
lavage- and brush-collected self-samples for CIN3+ detection. Several
studies have described DNA methylation of promotor regions of genes
as candidate biomarkers [55]. Although some are highly promising for
future application in molecular cervical screening, not all markers per-
form well and only a limited number of DNA methylation markers
have been studied extensively as triage tests for HPV-positive cervical
scrapes and/or self-samples [22,23,47,56]. Differences in clinical perfor-
mance ofmethylationmarkers between sample types have been report-
ed before [41]. These differences are most likely related to intrinsicTable 1
Clinical performance of FAM19A4/mir124-2methylationmarker analysis, HPV16/18 genotyping
by self-sample type.
Self-sample Triage marker n1/N1 Sensitivity
(%)
(95%CI) n2/N
Lavage FAM19A4/mir124-2methylation 55/78 70.5 (60.4–80.6) 211/
Brush FAM19A4/mir124-2methylation 50/72 69.4 (58.8–80.1) 139/
Lavage HPV16/18 genotyping 51/78 65.4 (54.8–75.9) 202/
Brush HPV16/18 genotyping 50/72 69.4 (58.8–80.1) 129/
Lavage FAM19A4/mir124-2methylation
and/or HPV16/18 genotyping
69/78 88.5 (81.4–95.6) 168/
Brush FAM19A4/mir124-2methylation
and/or HPV16/18 genotyping
61/72 84.7 (76.4–93.0) 100/
CIN = cervical intraepithelial neoplasia; CI = conﬁdence interval; PPV = positive predictive v
total number of disease cases; n2 = number of test negative non-disease cases; N2 = total nuunderlying variability in cellular composition and proportion of
hypermethylation-positive cervical cells indicative for CIN lesions be-
tween various types of samples. Regarding self-samples, only lavage
samples have been extensively investigated by DNA methylation
marker analysis so far. The JAM3/EPB4/TERT/C13ORF18 marker panel
showed good feasibility on lavage self-samples [33] and the MAL/
mir124-2marker panel performed non-inferior to cytology triage via a
physician-taken cervical scrape for the detection of CIN2+ [22,41]. For
brush samples, only a feasibility study evaluating JAM3/EPB4/TERT/
C13ORF18methylation has been published [32], but no clinical perfor-
mance data in large series have been reported. The equal clinical perfor-
mance of FAM19A4/mir124-2methylation analysis in both HPV-positive
lavage and brush self-samples as assessed on large sample series herein,
suggests that this assay is an attractive, directly applicable molecular
triage tool for self-samples, independent of the collection device used.
Further prospective studies are warranted to clinically validate HPV
testing combined with FAM19A4/mir124-2 methylation-based triage
on self-collected (cervico-)vaginal samples in cervical screening studies.
The qMSP assay used in this study allows fast and reliable read-out
of multiple methylation markers and a reference gene in one assay. As
such, the methylation test safes clinical material, time and costs and
improves quality control. Using a dichotomized outcome, the assay
provides a clinical decision point to refer an HPV-positive woman for
colposcopy or not. The advantages of our study are the evaluation of
large, independent series of different self-sample types, and the use of
a standardized assay. A limitation of our study can be seen in the differ-
ence in follow-up time between the cohorts used in this study









311 67.8 (62.7–73.0) 35.5 (28.0–43.0) 90.2 (86.4–94.0) 39.8
182 76.4 (70.2–82.6) 53.8 (43.6–63.9) 86.3 (81.0–91.6) 36.6
311 65.0 (59.7–70.3) 31.9 (24.7–39.1) 88.2 (84.0–92.4) 41.1
182 70.9 (64.3–77.5) 48.5 (38.9–58.2) 85.4 (79.8–91.1) 40.6
311 46.0 (40.4–51.5) 29.1 (23.3–34.9) 94.1 (90.3–97.8) 60.9
182 54.9 (47.7–62.2) 42.7 (34.6–50.8) 90.1 (84.5–95.7) 56.3
alue; NPV = negative predictive value; n1 = number of test positive disease cases; N1 =
mber of non-disease cases.
346 L.M.A. De Strooper et al. / Gynecologic Oncology 141 (2016) 341–347in the PROHTECT-2 cohort, the far majority of women (i.e., 69/72)
women developed CIN3+ during the ﬁrst 18 months of follow-up
and only 3/72 women during the 2nd 18 months of follow-up. As the
number of women diagnosed with CIN3+ during the 2nd 18 months
in PROHTECT-2 is limited, we feel that this has nomeaningful inﬂuence
on the clinical performance ﬁgures presented in this work for both
cohorts.
To the best of our knowledge, no other methodology is cur-
rently available that can be reliably applied directly to self-collected
(cervico-)vaginal specimens, and has similar clinical sensitivity and
clinical speciﬁcity ﬁgures for the triage of HPV-positive women follow-
ing self-sampling as the FAM19A4/mir124-2 assay described herein.
Cytology is a widely accepted triage test for HPV-positive women,
but cytology triage following HPV self-sampling requires an additional
cervical scrape taken by a physician [22,29]. Furthermore, it has been
proposed that methylation analysis has a high detection sensitivity
for cancer and advanced cervical lesions having a high short-term
progression risk for cancer [35]. In contrast, cytology detects with a
moderate sensitivity all morphological cellular abnormalities associated
withmost, but not all, CIN2/3 and cancer [31]. Indeed,methylation anal-
ysis has shown to detect all cervical carcinomas [35,38], as conﬁrmed
herein for limited numbers (n = 13 and n = 12 for lavage and brush
self-samples, respectively). Nonetheless, part of CIN2 and few CIN3 le-
sions are likely to remain undetected when a methylation marker-
based triage strategy is used. Based on our previous work, these lesions
are likely early-onset or incident lesions with a low progression-risk to
invasive cancer [35]. As clinicians prefer to also detect these early-onset
lesions, combined molecular triage by FAM19A4/mir124-2methylation
marker analysis and HPV16/18 genotypingmay be considered for triage
of women with an HPV-positive self-sample [30]. Indeed, CIN3+ sensi-
tivities increased when adding HPV16/18 genotyping to FAM19A4/
mir124-2methylation analysis. These ﬁndings are in line with Verhoef
et al. [30] showing that combined molecular triage by MAL/mir124-2
and HPV16/18 genotyping on HPV-positive lavage self-samples leads
to signiﬁcantly higher sensitivities for CIN3+, yet at the cost of a
lower speciﬁcity.
5. Conclusion
FAM19A4/mir124-2 methylation analysis performs equally well
in HPV-positive lavage- and brush self-samples to identify women
with CIN3+. In combination with HPV16/18 genotyping, signiﬁcantly
higher CIN3+sensitivities are obtained, at decreased speciﬁcity. Further
validation of molecular cervical screening with self-sampling in
population-based study is warranted.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ygyno.2016.02.012.
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